INTERVENTIONALAuthorised2023-504439-42-03
Phase II, Placebo-controlled trial of Cannabidiol for the treatment of alcohol dependence (PLACONCANALDE)
Determine the change in the Timeline Follow-back (TLFB) assessment of alcohol consumption and the change in percent Carbohydrate Deficient Transferrin (CDT) in serum, to evaluate the therapeutic potential of CBD in the management of patients with alcohol dependence who are seeking treatment to achieve abstinence.
Locally preserved from EU Clinical Trials Information SystemOpen EU Clinical Trials Information System↗last source update 2026-06-09
What this record can show
Protocol only - no registry results posted
This locally preserved record separates the registered protocol from source-reported registry results. Neither is a treatment recommendation.
Registry facts
Study at a glance
- Phase
- PHASEII
- Enrollment
- 118 (ACTUAL OR ANTICIPATED)
- Start date
- Not reported
- Sponsor
- Hospital Universitario 12 De Octubre
- Design
- Not reported
- Locations
- 0
- Results record
- Not present in registry snapshot
Phase II trial
alcohol dependencealcohol dependence
Linked local records
Related local records
Local links use governed condition terms or exact source-reported intervention names. They are navigation candidates, not efficacy claims.
Cannabinoids and active compounds
No governed compound link was found.
Medicines
No exact medicine-name link was found.
Interventions
What was registered
No structured intervention was reported.
Eligibility
Population and criteria
- Sex
- Not reported
- Minimum age
- Not reported
- Maximum age
- Not reported
- Healthy volunteers
- Not reported
Eligibility criteria
- ['Males and females aged 18-65', 'DSM-5 diagnosis of moderate or severe AUD.', 'Able to provide voluntary informed consent.', 'At least 8 heavy drinking days (4 or more drinks for a woman, 5 or more drinks for a man) in the 30 days prior to screen.', 'If of childbearing potential (male or female), are willing to use approved form of contraception from screening for duration of the trial.', 'Able to provide at least two locators.', 'Endorse desire to cut down or stop drinking.', 'Endorse desire to cut down or stop drinking.'] ['Current alcohol withdrawal (CIWA-Ar score >7).', 'Pregnancy or lactation.', 'Current use of exclusionary medications, including cannabinoids; treatments for addictions including alcohol; moderate to strong inhibitors of CYP3A4 or CYP2C19; medications metabolized primarily by CYP3A4, CYP3A5, or CYP3A7; and medications with a narrow therapeutic index which are substrates of UGT1A9, UGT2B7, CYP2C8, CYP2C9, CYP2C19, CYP1A2, or CYP2B6.', 'Allergy to any ingredient of the study compound.', 'Current treatment for AUD, with exception of AA/12-step treatment/mutual-help groups-.', 'No inpatient psychiatric treatment in the last 12 months, with the exception of detox and extended Emergency Department stays.', 'A positive urine drug screen for THC, cocaine and/or opioids at screen.', 'Exclusionary medical conditions (e.g., current severe alcohol withdrawal requiring medical hospitalization, significantly impaired liver function).', 'DSM-5 diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder.', "High risk of adverse emotional or behavioral reaction based on investigator's clinical evaluation (e.g., evidence of serious personality disorder, antisocial behavior, serious current stressors, lack of meaningful social support).", 'Current significant suicidality (assessed using the C-SSRS), any suicidal behavior in the past 12 months, or any history of serious suicide attempts requiring hospitalization, or current significant homicidally.', 'History of severe Traumatic Brain Injury (LOC > 24 hours).', 'DSM-5 diagnosis of current mild cannabis use disorder and/or moderate or severe substance use disorder for a substance other than alcohol or nicotine.', 'Significant laboratory abnormalities, including significantly impaired liver function, serious abnormalities of complete blood count or metabolic panel.', 'Active legal problems likely to result in incarceration within 12 weeks of treatment initiation.']
Publications
Locally readable linked articles
0No exact PMID-linked public article is currently readable locally.
Snapshot provenance
- Snapshot
- 0f1b01f3-c71a-492a-bdb0-4fd648871a8d
- Retrieved
- 25/08/2026, 17:11:59
- SHA-256
- 5f406e338443c74594bdffb14c767279b2df6b4264b821e96f532abe97f2fd7e